TP53 and colorectal carcinoma: An additional study has addressed the prognostic relevance of TP53 mutations (at codons 273, 248, 175, 282, and 245), MMR deficiency (measured as microsatellite instability status—MSI), and KRAS mutation status in a group of patients with stage III CRC, randomly assigned for adjuvant treatment with fluorouracil-based chemotherapy.